ClinicalTrials.gg
CompletedNCT05461430TraveraRTGxUpdated Apr 13, 2026

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

An observational study in Pleural Effusion, Malignant, Ascites, Malignant and Carcinoma, sponsored by Travera Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Travera Inc · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
72
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

02

Conditions studied

  • Pleural Effusion, Malignant
  • Ascites, Malignant
  • Carcinoma
  • Carcinoma, Hepatocellular
  • Carcinoma, Renal Cell
  • Carcinoma, Renal
  • Carcinoma, Small Cell
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Pancreatic Ductal
  • Carcinoma, Neuroendocrine
  • Carcinoma, Thymic
  • Carcinoma, Pancreatic
  • Carcinoma Breast
  • Carcinoma, Ovarian
  • Carcinoma Bladder
  • Carcinoma of Unknown Primary
  • Carcinoma of the Head and Neck
  • Carcinoma of the Oropharynx
  • Carcinoma of the Larynx
  • Carcinoma of the Bladder
  • Carcinoma of Esophagus
  • Carcinoma of the Nasopharynx
  • Carcinoma of the Penis
  • Carcinoma of the Cervix
  • Carcinoma of the Anus
  • Carcinoma of the Vulva
  • Carcinoma of the Appendix
  • Carcinoma of the Oral Cavity
  • Cholangiocarcinoma
  • Melanoma
  • Mesothelioma
  • Pancreatic Cancer

Keywords

  • Breast Cancer
  • Lung Cancer
  • NSCLC
  • Occult Cancer
  • Ovarian Cancer
  • Melanoma
  • Mesothelioma
  • Gastrointestinal Stromal Tumor
  • Gastric Cancer
  • Colon Cancer
  • Cervical Cancer
03

In context

Pleural Effusion, Malignant

169 studies on the registry are indexed under Pleural Effusion, Malignant; 39 are open to participants now.

This study's enrollment of 72 is below the median of 112 across 37 observational studies indexed under Pleural Effusion, Malignant.

Browse Pleural Effusion, Malignant studies →

Lead sponsor

Travera Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This pilot study will utilize samples from as many as 200 patients with a known carcinoma undergoing routine draining of malignant fluids or sampling of their tumor tissue for diagnostic or palliative standards of care (SOC).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is ≥18 years of age
  2. Written provided by patient
  3. Diagnosis of any kind of carcinoma
  4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle is clinically indicated as part of SOC
  5. Proceeding onto therapy for treatment
  6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion criteria

Exclusion Criteria:

  1. Lack of
  2. Unable to obtain sufficient sample
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
72 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. BOR

    Best overall response

    Time frame: 12 months

Secondary outcomes

  1. PFS

    Progression Free Survival

    Time frame: 24 months

07

Study locations

1 site
  • xCures
    Oakland, California 94612, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05461430
Lead sponsor
Travera Inc
Collaborators
xCures
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Jul 15, 2022
Primary completion
Mar 23, 2026
Completion
Mar 23, 2026
Last update
Apr 13, 2026

Study contacts

Mark Stevens, Phd
principal investigator · Travera Inc
Rob Kimmerling, Phd
principal investigator · Travera Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion